Clinical impact of early brain atrophy in clinically isolated syndromes

Mult Scler. 2013 Dec;19(14):1878-86. doi: 10.1177/1352458513488231. Epub 2013 May 7.

Abstract

Background: The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged.

Objectives: We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS.

Methods: We assessed 176 patients with CIS within 3 months of onset, clinically and by conventional magnetic resonance imaging (MRI) scans, at baseline and 1 year after clinical onset. We determined the percentage of brain volume change (PBVC) and the brain parenchymal (BPF), grey matter (GMF) and white matter (WMF) fractions.

Results: The mean follow-up time was 53 months (SD = 16.8): 76 patients (43%) experienced a second attack, 32 (18%) fulfilled MRI-only 2005 McDonald criteria and 68 (39%) remained as CIS. Statistically significant decreases in the volume measures tested were observed in patients with a second attack, for BPF and PBVC; in both MS groups for GMF; whereas in all groups, the WMF was unchanged. Patients with a second attack had larger PBVC decreases (- 0.65% versus + 0.059%; p < 0.001). PBVC decreases below - 0.817% independently predicted shorter times to a second attack.

Conclusions: Global brain and grey matter volume loss occurred within the first year after a CIS; brain volume loss predicted conversion to MS.

Keywords: Brain atrophy; brain volume; clinically isolated syndrome; disability; grey matter; magnetic resonance imaging; multiple sclerosis.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Atrophy
  • Brain / drug effects
  • Brain / pathology*
  • Demyelinating Diseases / drug therapy
  • Demyelinating Diseases / pathology*
  • Disability Evaluation
  • Disease Progression
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / pathology*
  • Organ Size
  • Prospective Studies
  • Recurrence
  • Time Factors
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Immunologic Factors